Is Melanoma a Hormone-Dependent Cancer or a Hormone-Responsive Cancer? by Ramaraj, Pandurangan
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3
Is Melanoma a Hormone-Dependent Cancer or a
Hormone-Responsive Cancer?
Pandurangan Ramaraj
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.76499
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Pandurangan Ramaraj
Additional information is available at the end of the chapter
Abstract
Melanoma, a potentially fatal form of skin cancer is on the rise. This review not only 
underlines the close connection between skin and endocrine system, but also lists evi-
dences from multiple sources epidemiological, clinical, previous in vivo and in vitro stud-
ies regarding the involvement of sex steroids in melanoma. Incidentally, clinical studies 
underscored the involvement of sex steroids in the protective function in melanoma in 
menstruating females. But, none of these studies identified the sex steroids involved in 
the protective function in melanoma in menstruating females. The sex steroid involved 
in this innate protection in melanoma in menstruating females has not been investigated 
by scientists, though advances have been made in immunotherapy with accompanying 
side effects. In this context, our in vitro studies on mouse and human melanoma cell 
lines, along with literature survey, pointed to progesterone as the possible female sex 
steroid involved in the protective function in melanoma. Based on our findings and pre-
vious studies, it is concluded in this review that melanoma is not a hormone-dependent 
cancer. But, it may be a hormone-sensitive or responsive cancer, as hormones (sex ste-
roids) inhibited melanoma cell proliferation in vitro. This new understanding will help 
in developing new therapy or target for melanoma treatment.
Keywords: melanoma, epidemiological studies, clinical studies, in vivo and in vitro 
studies, protective function, progesterone, hormone-responsive cancer
1. Introduction
The question that has been raised over the years, whether melanoma is a hormone-dependent 
cancer or not still lacks a clear-cut answer [1–4]. However, in this review, an attempt has 
been made to collect evidences from multiple sources to point out the nature of melanoma. 
Melanoma, the fatal form of skin cancer accounts for less than 2% of skin cancer, but it is 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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responsible for 75% of deaths due to skin cancer [5]. According to the American Cancer Society 
reports known as Cancer Statistics, melanoma is on the rise. In 2018, in the United States, 
91,270 new cases will be diagnosed with an estimated 9320 deaths [6]. Melanoma occurs 
mostly on the skin [7]; however, some rare forms of melanoma can occur in other areas such 
as cornea, uvea, and gastrointestinal tract [7]. Epidemiological data indicated an increased 
mortality rates in males than in females [8], suggesting a sex difference. Clinical studies 
showed that menstruating females were better protected (delayed metastasis and increased 
survival) in melanoma than postmenopausal women and men of any age [9], clearly indicat-
ing the role of sex steroid hormones in the protection function. It is important to point out that 
skin itself functions as an endocrine organ [10], even though it is not acknowledged as one. 
Skin possesses many of the enzymes necessary for synthesis of steroid hormones [11]. In fact, 
most of the peripheral conversions of dehydroenpiandrosterone (DHEA) and androstenedi-
one (AD) to testosterone and estradiol take place in the skin [12]. This area of endocrinology 
is known as intracrinology [12]. In addition, skin is also a target organ for various hormones. 
Sex steroids such as androgens, estrogens, and progestins are essential for a healthy skin [13]. 
Melanocyte, which is transformed to melanoma cell is also under the influence of melano-
cyte-stimulating hormone (MSH) from pituitary [14]. Hence, it is natural to ask the question 
whether melanoma is a hormone-dependent cancer like breast, prostate, and endometrial 
cancers. Generally, melanoma is not labeled as a hormone-dependent cancer because of the 
belief that UV rays from the Sun is the major cause for melanoma [15]. UV rays cause DNA 
damages and other inflammatory changes in the skin, which result in skin cancer. About 90% 
of melanoma is caused by environmental factors such as UV rays, radiations, and only 10% 
is inherited in the family. So, melanoma is never considered as a hormone-dependent cancer. 
However, existing evidences point to a hormone relatedness or a hormone-responsive nature 
of melanoma cancer:
1. Evidences of relationship between skin and endocrine system: there is a close connection 
between skin and endocrine system, as shown by the following examples.
a. All the components of a functional hypothalamo-pituitary-adrenal axis analog are pre-
sent in the skin.
b. Presence of enzymes involved in steroid hormone synthesis in skin cells: the level of 
local steroid production depends on the expression of androgen- and estrogen-synthe-
sizing enzymes present in specific cell types. Five major enzymes are involved in the 
activation and deactivation of androgens in the skin [13].
c. Actions of sex steroid hormones on skin: skin is a target organ for sex steroid hormones. 
Androgens are essential for differentiation and growth of Sebocyte and hair growth. 
Estrogen is responsible for skin pigmentation and skin cancer. Progesterone functions, 
though not clear is essential for treating acne [13].
d. Endocrine disorders manifested on the skin:
i. Association of insulin resistance and metabolic syndrome with acne: post-adolescent 
male patients with acne more commonly have insulin resistance [16]. This resistance 
may be a stage of prediabetes and the patients may develop hyperinsulinemia or 
type 2 diabetes in the future.
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ii. Association of cutaneous findings and systemic abnormalities in women suspected 
of having polycystic ovary syndrome (PCOS): Hirsutism and acne are the most reli-
able cutaneous markers of PCOS and require a comprehensive skin examination to 
diagnose [17].
iii. Psoriasis severity may influence type 2 diabetes risk: people living with psoriasis are 
not only at higher risk of type 2 diabetes, but their risk also rises in line with the skin 
disease’s severity [18].
It is evident from the above mentioned examples that skin is not only an endocrine organ which 
produces various hormones, but also has a close relationship with systemic endocrine system.
2. Evidences from epidemiological data
According to the epidemiological SEER data [8] known as Surveillance, Epidemiology and 
End Results program, a database maintained by NCI, there has been an increase in the inci-
dence of melanoma. The incidence of melanoma (‘03-‘07) for men and women were 26.7 per 
100,000 and 16.7 per 100,000 respectively. There has been an increase in death rate also. Even 
in the death rate, there was a difference between males and females. The mortality rate for 
males was 4.0 per 100,000, whereas for females it was 1.7 per 100,000. Males have increased 
mortality rate than females. Death rate was cut more than half in females. Similarly, malignant 
melanoma database (1971–2012) maintained by UK Cancer Research Council [19] also showed 
that the morality rate was higher in males than in females over the years. The data [20] was 
almost similar from Australian continent, where the incidence of melanoma is the highest in 
the world. From 1982 to 2016, the number of melanoma diagnosed in Australia increased from 
3526 to an estimated 13,280. The age-standardized incidence rate increased for both males and 
females, from 28 to 60 cases per 100,000 males, and from 26 to 39 cases per 100,000 females. 
Data showed males were more prone to melanoma than females [20]. Thus epidemiological 
data from three continents clearly showed that males were more affected by melanoma than 
females. These gender differences in melanoma demand an investigation of the effect of sex 
hormones on this malignancy.
3. Evidences from clinical studies
Clinical studies supported the epidemiological findings. Clinical studies showed that men-
struating females were better protected (delayed metastasis and increased survival) in mela-
noma than post-menopausal women and men of any ages [9]. This very difference between 
menstruating females and postmenopausal women clearly indicated the involvement of ste-
roid hormones in protecting menstruating females in melanoma. However, these data base 
were not correlated with the steroid status of females. Studies published between 1977 and 
1966 showed women had better survival in all but 4 out of 22 epidemiologic studies [21]. Two 
female hormones could be involved in rendering protection, namely estrogen and proges-
terone. First, estrogen as the hormone protecting menstruating females in melanoma: estro-
gen receptor antagonist tamoxifen was evaluated as a single agent in 12 studies covering 213 
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patients with metastatic melanoma cancer [22]; the response rate was only 7%. Moreover, 
estrogen receptors were found in some cancers only by biochemical and histochemical tests 
but not by the immunohistochemical tests using monoclonal antibodies [23]. Second, proges-
terone as the possible female sex hormone involved in the protection: there were only limited 
in vitro studies [24, 25] and they were also not tied to the protective function in melanoma. 
According to the data published on pregnancy and melanoma, several studies reported statis-
tically no significant differences in survival rates between controls (non-pregnant women with 
malignant melanoma) and women diagnosed with melanoma stage I or II during pregnancy 
[26–28]. Studies also found no association between melanoma and oral contraceptives [29, 30]. 
Data on the relationship between melanoma and hormone replacement therapy were meager 
and it seemed that exogenous hormones did not influence the risk for malignant melanoma 
[31, 32]. So, clinical studies underlined the involvement of female sex steroid hormones in 
protecting menstruating females in melanoma. But, these clinical studies did not identify the 
exact female hormone involved in the protection.
4. Evidences from animal studies
Animal studies also showed the involvement of sex steroid hormones in the regulation of 
melanoma growth and there were also differences in the regulation of melanoma growth 
between male and female mice.
a. Female survival benefit with metastatic melanoma was observed, when melanoma cells 
produced liver metastases preferentially in male compared to female mice [33].
b. In another study, estrogen receptor-positive human melanomas cells grew more slowly in 
females than in males mice [34].
c. Similarly, dihydrotestosterone was shown to stimulate proliferation. But, in a follow-up 
study, male mice transplanted with melanoma showed increased survival after treatment 
with anti-androgen receptor hydroxyflutamide [35].
d. Male mice were significantly more susceptible to carcinogen-induced skin cancer than 
female mice [36].
e. Similarly male mice were more susceptible to UV-B induced skin carcinogenesis than fe-
male mice [37]
f. Research work presented in one study showed that metapristone (a metabolite of mife-
pristone (RU-486)) had a remarkable effect of preventing cancer metastasis of B16-F10 cells 
in vivo compared with mifepristone [38].
5. Evidences from previous cell-culture studies
Apart from epidemiological, clinical, and in vivo animal studies, various in vitro studies using 
a variety of melanoma cell lines showed the inhibitory effect of steroid hormones on mela-
noma cell growth, suggesting melanoma could be a hormone-sensitive or responsive cancer.
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a. In one study, 2-methoxyestradiol (2-ME), an estrogenic metabolite inhibited the growth 
of all melanoma cells tested, without inhibiting the growth of non-tumorigenic cells [39].
b. Data from another study suggested that 17-β-estradiol, progesterone, and dihydrotestos-
terone suppressed the growth of melanoma cells by inhibiting interleukin-8 production in 
a receptor-dependent manner [25].
c. However, Feucht et al. investigated three human melanoma cell lines and found no effect 
either by estradiol or tamoxifen on melanoma cell growth in vitro [34].
d. Another in vitro study indicated a direct inhibitory effect of testosterone on growth of an 
amelanotic strain which in vivo grew faster in female hamsters [40].
e. The findings in another study indicated that glucocorticoids exerted some influence on 
the growth of human melanoma cells and this effect was mediated through glucocorticoid 
receptor [41].
f. Only study which showed a stimulatory effect was with melanocyte, where α-MSH stimu-
lated melanocyte proliferation in a dose-dependent manner, but its stimulatory effect re-
quired bFGF and/or the activation of protein kinase C [42].
g. Another in vitro study showed that melatonin at physiological concentrations (1 nM to 10 
pM) inhibited metastatic mouse melanoma (B16BL6) cell growth [43].
6. Evidences from our studies on mouse melanoma (B16F10) cell line
a. Progesterone effect on mouse melanoma (B16F10) cell growth: based on previous research 
work and literature survey, initially four sex steroids were checked for their effect on 
mouse melanoma (B16F10) cell growth [44]. Of the four steroids checked [dehydroepian-
drosterone (DHEA), androstenedione (AD), testosterone (T) and progesterone (P)], pro-
gesterone showed significant inhibition (87%) of mouse melanoma cell growth. Though 
other steroid hormones also showed inhibition of cell growth, but it was not as significant 
as that of progesterone inhibition (Figure 1).
b. Progesterone dose-response study with mouse melanoma cells: as the initial experi-
ment was carried out at high concentrations (100, 150, 200 μM) of hormones, a follow-
up dose-response study was carried out with progesterone alone. Dose-curve study 
with progesterone showed a dose-dependent decrease in mouse melanoma cell growth 
(Figure 2).
c. Further studies with mouse melanoma cell line: further studies (data not shown) showed 
that the effect of progesterone on mouse melanoma cells was not a toxic, not a spurious 
or not a non-specific effect [44]. The only other steroid which showed a significant inhi-
bition of mouse melanoma cell growth was progesterone-receptor antagonist RU-486, a 
synthetic steroid (Figure 3).
d. Mechanism of progesterone action on mouse melanoma cell line: since RU-486 also showed 
a dose-dependent inhibition of mouse melanoma cell growth, it was decided to find out 
whether the actions of progesterone and RU-486 were mediated through progesterone 
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receptor. A co-incubation study was carried out with fixed concentration of progester-
one (50 μM) and varying concentrations of RU-486 (10, 50, 100 μM). Co-incubation study 
showed an additive effect (data not shown) on mouse melanoma cell growth suggesting 
that the action was not mediated through progesterone receptor [44].
Figure 1. Various steroid hormones effect on mouse melanoma (B16F10) cell growth: three androgens (DHEA, AD, T) 
and one female sex steroid hormone (P) were checked for their effect on mouse melanoma cell growth at 100, 150, and 
200 μM concentrations. Cells were incubated with the hormones separately for 48 h. After 48 h, cell growth was assessed 
by MTT assay. All the steroids checked showed dose-dependent decrease in cell growth. But, progesterone showed a 
significant inhibition of cell growth (87%) at 200 μM concentration.
Figure 2. Dose-response study with mouse melanoma cell line: since the initial study was carried out at high 
concentrations, a dose-response study was carried out with progesterone starting from 1 to 200 μM. Progesterone 
showed a dose-dependent decrease in mouse melanoma cell growth with significant inhibition at 200 μM concentration. 
Cell growth was monitored by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
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7. Evidences from our studies on human melanoma (BLM) cell line
a. Dose-response study with progesterone and RU-486 on human melanoma cell line: the 
sex steroids (progesterone and RU-486), which showed inhibition on mouse cell line were 
checked on human melanoma (BLM) cell line for their effect [45, 46]. Progesterone and RU-
486 also showed a dose-dependent inhibition of human melanoma cell growth (Figure 4).
Figure 3. Comparison of dose-response curves of progesterone and RU-486: both progesterone and RU-486 were treated 
separately for 48 h. After 48 h, cell growth was assessed by MTT assay. Dose-response curve of RU-486 was compared 
with that of progesterone. The dose–response curves were very similar to each other.
Figure 4. Dose-response study of progesterone and RU-486 on human melanoma cell line: progesterone and RU-486 
were incubated separately with human melanoma cells for 48 h. After 48 h of incubation, cell growth was measured 
by MTT assay. Dose-response study of both progesterone and RU-486 showed a dose-dependent decrease of human 
melanoma cell growth.
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b. Mechanism of action of progesterone on human melanoma cells: since progesterone and 
RU-486 separately showed a dose-dependent inhibition of human melanoma cell growth, 
it was decided to find out whether these actions were mediated through progesterone 
receptor on human melanoma cell line. Therefore, co-incubation study, just like the one 
on mouse melanoma cell line was carried out. Co-incubation study showed that the effect 
was not mediated through progesterone receptor (Figure 5). In fact, co-incubation of the 
two steroids (progesterone and RU-486) showed an additive effect on cell growth inhibi-
tion, suggesting the actions were mediated through two different mechanisms.
c. Mechanism of inhibition of human melanoma cell growth by progesterone: since the co-
incubation study suggested that the mechanism of action of progesterone and RU-486 
could be different, it was decided to find out the mechanism of inhibition of human mela-
noma cell growth by progesterone. After having ruled out necrosis and apoptosis as the 
mechanism of inhibition of cell growth, it was found out that autophagy was the cause 
for cell growth inhibition by co-incubating progesterone and 3-methyl adenine (3-MA) on 
melanoma cells. 3-methyl adenine (3-MA) had been used in various studies to check or 
Figure 5. Co-incubation of progesterone and RU-486: a fixed concentration of progesterone (10 μM) was co-incubated 
with varying concentrations of RU-486 (10, 50, 100 μM). Co-incubated cells showed an additive effect on cell growth 
inhibition, suggesting the action was mediated through different mechanisms and not through progesterone receptor.
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inhibit autophagy [47–49]. Therefore, the mechanism of inhibition of human melanoma 
cell growth by progesterone was due to autophagy (Figure 6).
d. Suppression of adhesion and migration functions of human melanoma cells by progester-
one: metastasis of cancer involves adhesion, migration, and invasion functions. Progester-
one ability to suppress metastasis was checked by in vitro adhesion and migration assays 
after treatment with progesterone for 48 h [50]. Progesterone at 100-μM concentration 
decreased adhesion function to 71% compared to untreated control cells at 100%. Similarly 
progesterone at 50 μM significantly decreased migration to 20% compared to untreated 
control cells at 100%. Adhesion and migration assays suggested that progesterone could 
be playing a role in delayed metastasis, as reported in clinical studies [9] (Figure 7).
Figure 6. Mechanism of human melanoma (BLM) cell growth inhibition by progesterone: after having ruled out necrosis 
and apoptosis as mechanism of inhibition, it was decided to find out whether autophagy was the mechanism of inhibition 
of cell growth. So, cells were co-incubated with progesterone and 3-MA (2 mM) for 48 h. After 48 h, cell growth was 
monitored by MTT assay. 3-methyl adenine (3-MA) partially rescued melanoma cell growth, showing a slight increase in 
co-incubated cell growth compared to progesterone alone treated cell growth. 3-methyl adenine (3-MA) had been shown 
to disrupt the formation of autophagsome/lysosomal degradation in various studies [47–49].
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8. Summary
There is a close connection between skin and endocrine system, as shown by the neuroen-
docrine properties of skin. Skin not only functions as an endocrine organ but also as a target 
organ for various hormones. Epidemiological studies highlighted the differences in mortal-
ity rate between males and females and hinted the involvement of hormones in melanoma. 
Clinical studies pinpointed the role of sex steroids, mainly female sex steroids, in melanoma. 
Animal studies also highlighted the involvement of sex steroids in melanoma. In vitro studies 
with steroid hormones showed inhibition of melanoma cell growth. Our studies showed the 
in vitro effect of progesterone on mouse and human melanoma cell growth. In our studies, 
progesterone showed significant inhibition of mouse and human melanoma cell growth. The 
mechanism of inhibition was due to autophagy and the effect was not mediated through pro-
gesterone receptor. In vitro study also showed suppression of adhesion and migration func-
tions after progesterone treatment, suggesting progesterone could be involved in delayed 
metastasis of cancer. This in vitro finding supported the clinical studies which showed men-
struating females (whose progesterone level vary between 1000 and 1500 ng/dL) were bet-
ter protected in melanoma than post-menopausal women (whose progesterone level vary 
between 20 and 100 ng/dL) and men of any age. A similar study with different human mela-
noma (A375, A875) cell lines by Fang et al. [51] also showed that progesterone and RU-486 
inhibited melanoma cell growth and this effect was also not mediated through progesterone 
receptor. Similar result was observed in another study using progesterone and the same mela-
noma cell lines by Moroni et al. [31]. Kanda and Watanbe [25] had already shown the inhibi-
tion of human melanoma cells by progesterone. Thus the inhibition of melanoma cell growth 
Figure 7. Suppression of adhesion and migration functions by progesterone: human melanoma cells were treated 
with progesterone for 48 h in petri dishes. After 48 h, cells were harvested from control and progesterone treated cells. 
Adhesion assay was carried out in a 96 well plate with 30,000 cells/wells. Cells were incubated for 60 min and washed. 
Cells attached to the plate were fixed with 2% paraformaldehyde and stained with 0.2% crystal violet dye. Purple color 
dye was eluted with isopropanol and assayed at 570 nm in a plate reader. For migration assay, treated cells were placed 
in a 24 well plate and allowed to become confluent. Cells were scratched in the middle of the plate with a tip, which was 
considered as 0 time point and cells were allowed to incubate for 24 h. After 24 h, percentage of cells migrated to the 
cleared space was calculated with a software.
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by progesterone was observed by 3 other different groups. Thus, the preceding studies, our 
own studies, and previous studies by others lend support to the idea that melanoma is ame-
nable to hormone action and that melanoma is sensitive or responsive to steroid hormones.
9. Conclusion
Evidences from multiple sources (epidemiological, clinical, in vivo, and in vitro) suggested 
the involvement of hormones in melanoma and that melanoma was amenable to hormone 
action. But, unlike breast, ovary, and prostate cancers, addition of hormones did not stimu-
late proliferation of melanoma cells, suggesting melanoma was not a hormone-dependent 
cancer. However, addition of hormones suppressed melanoma cell proliferation, suggest-
ing melanoma might be a hormone-sensitive or responsive cancer. Therefore, acquisition of 
melanoma may not be hormone dependent, but survival (suppression of cancer cell prolif-
eration) in melanoma may be hormone dependent. Hence, based on epidemiological find-
ings, clinical studies, literature reports of previous in vivo and in vitro experiments, and 
our own experiments, melanoma may be considered as a hormone-sensitive or responsive 
cancer. This understanding will help in generating new therapy or therapeutic target for 
melanoma treatment.
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